Trial Profile
A Phase Ib Randomized Open Label Study Between Once-every-two-weeks and Once-every-four-weeks Treatment of CGC-11047 in Patients With CNV Due to Age Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2014
Price :
$35
*
At a glance
- Drugs PG 11047 (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Progen Pharmaceuticals Inc
- 25 Sep 2014 New trial record